Singapore

The Health Sciences Authority (HSA) is Singapore's primary regulatory authority for health products, operating under the Health Products Act (HPA) and its associated Health Products (Medical Devices) Regulations, Health Products (Therapeutic Products) Regulations, and In-Vitro Diagnostic (IVD) regulations. HSA oversees the registration, licensing, and post-market surveillance of therapeutic products (pharmaceuticals), medical devices, diagnostics, and, increasingly, digital health solutions. All health products intended for sale or supply in Singapore must be registered on the HSA's product registers before market entry, and manufacturers, importers, and wholesalers must hold the appropriate dealer's licences. HSA employs a risk-based classification system across all product categories, with review pathways scaled accordingly, ranging from expedited or abridged routes for well-established or internationally approved products to full review routes for novel or higher-risk submissions.

HSA accepts dossiers prepared in the Common Technical Document (CTD) format for therapeutic products and follows a structured technical file approach aligned with international standards such as ISO 13485 and IMDRF guidance for medical devices. A locally registered business entity is required to act as the product registrant, serving a role analogous to a local authorised representative. Singapore participates in the Association of Southeast Asian Nations (ASEAN) harmonisation initiatives, including the ASEAN Common Technical Dossier (ACTD) and ASEAN Common Technical Requirements (ACTR), facilitating regional alignment. HSA also operates several expedited review pathways, including the Innovative Drug Accelerated Review (InDAR) programme and the FAST-Track pathway for medical devices that address unmet clinical needs, and it maintains mutual reliance frameworks with reference regulators such as the US FDA, EMA, TGA, and Health Canada, enabling abridged reviews based on prior approvals from these agencies. Recent reforms have focused on strengthening the regulatory framework for Software as a Medical Device (SaMD) and AI-enabled health technologies, with updated guidance published to address clinical validation, cybersecurity, and post-market monitoring requirements for digital health products.

Public healthcare procurement in Singapore is centralised and coordinated primarily through the Ministry of Health (MOH) and its network of public healthcare institutions, which are organised into two vertically integrated public healthcare clusters: the National University Health System (NUHS) and the SingHealth group, alongside the National Healthcare Group (NHG). Large-scale procurement for public hospitals, polyclinics, and national programmes is typically conducted through competitive tender processes managed by the respective cluster procurement offices or through the Ministry of Finance's GeBIZ (Government Electronic Business) platform, which serves as the national e-procurement portal. The Health Promotion Board (HPB) and Agency for Care Effectiveness (ACE) play important roles in health technology assessment (HTA) and formulary decision-making, with ACE publishing guidance that influences formulary inclusion and reimbursement under national schemes such as MediShield Life and the Medication Assistance Fund (MAF). Suppliers must demonstrate clinical evidence, cost-effectiveness, and regulatory compliance to secure listing on national formularies or approved device registries.

Singapore's private healthcare sector is substantial and represents a significant parallel procurement channel, with private hospitals, specialist outpatient clinics, and general practitioners sourcing products independently through local distributors and authorised importers. Given Singapore's status as a high-income country and a regional healthcare hub, multilateral donor-funded procurement mechanisms such as those administered by UNICEF Supply Division, the Global Fund, Gavi, or USAID are not typically applicable to Singapore's domestic market. However, Singapore-based companies and institutions are active in supplying or facilitating procurement for these channels in the broader Asia-Pacific and Southeast Asian region. There are no formal local manufacturing preference policies mandated in public procurement, and Singapore's procurement framework is generally open and merit-based; however, the government actively supports the growth of Singapore's biomedical manufacturing sector through the Economic Development Board (EDB) and Enterprise Singapore, offering incentives that indirectly encourage local manufacturing investment and capability development.